China Healthcare Logistics - Shock Waves

Tech-enabled healthcare platforms to connect patients digitally with advice, medicine and healthcare services have been forerunners in China

 'Good Doctor', a $3 billion market-cap 'health-tech' industry leader with 440 million registered users as of June 2022, has gained recognition as subsidiary of data-rich insurer Ping An before a spin-off as 'Ping An Health and Technology' -  - in April 2018

• Highlighted  since January 2022, the Ping An Health stock [1833.HK] was issued a special dividend of HK$9.7 per share in December 2024 - Performance YTD (post dividend) on Hong Kong exchange exceeded 70% (as of August 2025)
• Exceptional OTC share performance accounts for this special dividend pay-out

In healthcare, e-Commerce giants Alibaba and JD.com   adopted similar strategies supported by the data troves of their rich ecosystems, combining on-line medical advice with their pharmacies (300 000 consultations per day as of March 2022 for Alibaba)

• With strong performance on the Hong Kong exchange (as of August 2025), both $10 billion marketcap Alibaba Health (0241.HK) and $19 billion market cap JD Health (6618.HK) are very poorly traded on OTC, surprisingly so

Partnerships between healthcare platforms and majors pharmaceutical firms - of which the March '21 distribution agreement between 111.Inc  and BeiGene  is an example - squares the circle by integrating medical advice, insurers, drugstores and pharmaceutical companies 

The tech approach has been adopted with gusto around the world, booking major successes during the pandemic for remote delivery  of healthcare

In the U.S., Teladoc Health - - an industry leader, has attracted competition from upstart American Well - - and from tech majors such as Amazon , with the Amazon Care program which is partnering with tele-health providers and Microsoft,  with a recently acquired Nuance Communications service that addresses the clinical documentation requirements from doctor-patient interactions

The selection is presented for information only because the industry segment is of special relevance - OTC pricing, performance and volatility of stocks are subject to major adjustments and require further research before investment

Since the companies are often very loosely traded on OTC markets, their performance may not reflect the trend and the actual performance on their home market, adjusted for currency shifts, is always the single most important indicator - their track record on OTC is strictly informative and will justify further research

With low trading volume on U.S. OTC markets for the listed shares, performance, volatility and drawdown calculations will be affected - these ratios do not reflect true performance, volatility and drawdown as these same shares are normally traded on their national exchange